Study of Liver Cancer in Dogs
Terms of The Study
A full screening will be performed prior to enrollment
Pet owner must be willing to transport their dog to and from the treatment center in Columbia, MO
Treatment includes Y90 radioembolization of hepatocellular (liver) cancer using novel, radiopaque Eye90 microspheres™
Treatment will be followed by examination and imaging at 3 months and 6 months
All dogs will receive radioembolization and a subset will be considered for subsequent, post-radioembolization partial liver resection
Participation may require a total of up to 5-visits over 6-months
Study benefits include:
•Radioembolization and surgical resection (if eligible)
•Follow-up physical exams and CT imaging at 3- and 6- months
•The opportunity to contribute to development of an important cancer therapy
Any type of dog diagnosed with a primary liver tumor is potentially eligible for study entry.
Candidates must also meet all the following requirements:
- Signed informed consent from the client prior to any study-related evaluation
- Be neutered or spayed
- At least one tumor must be great or equal to 3cm diameter, with no more than 3 tumors total
- Be a minimum of 12 kgs (26.4lb)
- Be more than 1 year old
- Have a reasonable life expectancy of more than 3 months without treatment
- Have pathology confirmed HCC and no other diseases or behavioral conditions that would interfere with study conduct
Background and Rationale
Radiation therapy uses high-energy radiation to shrink tumors and kill cancer cells. The radiation is intended to damage the DNA of the cancer cells beyond repair so that they stop dividing or die. Radioembolization with Y-90 is an advanced form of radiation therapy that delivers high-dose radiation with precision, enabling precise targeting of a tumor with minimal damage to nearby healthy tissue.
Y-90 has been used to successfully treat liver tumors in over 100,000 human patients. Studies have revealed that Y-90 is well-tolerated by the patient, results in minimal complications or side effects, maintains or improves the quality of life, and results in equivalent survival times when compared to surgery for patients with operable tumors.
This is a two-arm prospective study. At least 6 dog patients are planned for enrollment.
Arm 1: Eye90 microspheres™
Arm 2: Eye90 microspheres™ plus partial-liver surgical resection
Eligible patients will be treated once with Y-90 under a protocol consistent with the quality assurance practices of The College of Veterinary Medicine, University of Missouri.
If you have additional questions about this study please contact the Principal Investigator at the address below, or click the link to send an Email:
Jeffrey N. Bryan, DVM
Professor of Oncology
Halifax Office (Main Office)
155 Chain Lake Drive
Halifax, NS B3S 1B3
Orange County Office
555 Corporate Drive
Ladera Ranch, CA, 92694
ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical may change the products mentioned at any time without notice. ABK Biomedical Inc. is a Pre-clinical stage company engaged in the active research and development of new medical devices. ABK Biomedical products are considered investigational only and are not FDA cleared for use..
(C) Copyright 2019 – All International Rights Reserved – ABK Biomedical Inc.